MannKind has announced that it is holding a conference call on April 19 (corrected date from original post) for investment analysts to discuss plans for future distribution of Afrezza once the deal with Sanofi has expired. Hopefully, the company has a strategy to keep Afrezza on the market for those whom it has obviously helped tremendously.
I see this announcement today that there will be a conference call on April 19 (and how to listen)
http://investors.mannkindcorp.com/releasedetail.cfm?ReleaseID=964413
You are correct. The date of press release is today.
A little confusing on the company website. Thanks for the clarification.
Update: Mannkind has postponed the conference call today one week to Apr 26 at 5 pm ET due to “CEO emergency retinal detachment surgery”
details and how to participate next week:
http://investors.mannkindcorp.com/releasedetail.cfm?ReleaseID=965800
In the interim, the company has filed to offer up to $500 million in new securities, which could be a combination of common stock, preferred stock, debt and/or warranties. The company seems to be making an effort to go it alone, recently hiring two new senior executives, including a vice president of marketing.
hopefully one of our members here will be listening in to this this afternoon and report on what is said!
MannKind will relaunch post-Sanofi with its own sales staff of about 50-70 reps, targeting primarily endocrinologists. No national advertising campaign is planned until target doctors are educated. Insurance challenges will be addressed. Sanofi-branded Afrezza will be used until the third quarter, when MannKind will launch under its own brand. Some kind of capital infusion is likely, through debt or equity.
4 Likes
thanks @Jim2 for the summary.
I certainly hope that whatever they’re doing works out. I feel like the diabetes community as a whole was almost entirely unreceptive to a product that can improve so many of our lives… It’s a real warning sign unfortunately for others who might be pursuing advancements in the field when the target consumer just flat out isn’t interested in anything but pumps and cgms that don’t work nearly as well as the product you’re designing.
If this product fails, it’d be a very sad day for everyone with diabetes around the world, and a large part of the problem would have been our own attitudes and irrational fear of progress.
4 Likes